Lantern Pharma (LTRN) Shares Outstanding (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Shares Outstanding (Entity) came in at $11.3 million in Q1 2026, up 4.36% YoY from $10.8 million in Q1 2025, and little changed on a QoQ basis from $11.3 million in Q4 2025.
Lantern Pharma (LTRN) Shares Outstanding (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Shares Outstanding (Entity) data on file, last reported at $11.3 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 4.36% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (up 4.36% YoY) and the FY2025 annual result came in at $11.3 million, up 4.36% from the prior year.
- Shares Outstanding (Entity) was little changed at $11.3 million in Q1 2026, from $11.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $11.3 million in Q4 2025 to a low of $10.7 million in Q4 2023.
- A 5-year average of $10.9 million and a median of $10.8 million in 2022 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) fell 3.16% — and 2025, when it advanced 4.36%.
- Tracing LTRN's Shares Outstanding (Entity) over 5 years: stood at $10.9 million in 2022, then retreated by 1.25% to $10.7 million in 2023, then rose by 0.59% to $10.8 million in 2024, then grew by 4.36% to $11.3 million in 2025, then changed by 0.0% to $11.3 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $11.3 million (Q1 2026), $11.3 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | 11.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.25 Mn |
| Dec 31, 2025 | 10.90 Mn |
| Sep 30, 2025 | 10.83 Mn |
| Jun 30, 2025 | 10.78 Mn |
| Mar 31, 2025 | 10.78 Mn |
| Dec 31, 2024 | 10.76 Mn |
| Sep 30, 2024 | 10.76 Mn |
| Jun 30, 2024 | 10.76 Mn |
| Mar 31, 2024 | 10.74 Mn |
| Dec 31, 2023 | 10.84 Mn |
| Sep 30, 2023 | 10.86 Mn |
| Jun 30, 2023 | 10.86 Mn |
| Mar 31, 2023 | 10.86 Mn |
| Dec 31, 2022 | 10.85 Mn |
| Sep 30, 2022 | 10.84 Mn |
| Jun 30, 2022 | 10.83 Mn |
| Mar 31, 2022 | 10.88 Mn |
| Dec 31, 2021 | 10.90 Mn |
| Sep 30, 2021 | 11.19 Mn |
| Jun 30, 2021 | 11.18 Mn |